ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Public ClinicalTrials.gov record NCT02362035. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
Study identification
- NCT ID
- NCT02362035
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 161 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 20, 2015 (Actual)
- Primary completion
- Jul 14, 2020 (Actual)
- Completion
- Oct 27, 2025 (Actual)
- Last update posted
- May 13, 2026
2015 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85704 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Denver | Colorado | 80218 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Niles | Illinois | 60714 | — |
| Research Site | Boston | Massachusetts | 2215 | — |
| Research Site | Rochester | Minnesota | 55905-0001 | — |
| Research Site | Omaha | Nebraska | 68198-7680 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Greenville | South Carolina | 29605 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | San Antonio | Texas | 78217 | — |
| Research Site | Tyler | Texas | 75702 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Roanoke | Virginia | 24014 | — |
| Research Site | Vancouver | Washington | 98684 | — |
| Research Site | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02362035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02362035 live on ClinicalTrials.gov.